From Innovation to Impact: The Real Challenge for Biologicals
- 6 hours ago
- 4 min read
I recently returned from BioEx 2026, and it was an energizing and thought-provoking experience.
Over two days in Shanghai, I had the opportunity to listen, share, and engage in meaningful conversations with scientists, industry leaders, and innovators across the biological crop protection space. The diversity of technologies and the openness in discussing future challenges stood out to me the most.
What stayed with me were not only the formal sessions and panels, but also the many conversations in between: those moments in hallways, over coffee, and during transitions. There is clear progress across the industry, but also a shared recognition that important questions remain.
After reflecting on the meeting, one takeaway stands out: success today depends on turning strong science into solutions that farmers can use, trust, and scale.
One thought continues to stay with me:
The biological industry is no longer asking whether the science works. The real question now is how to make it work at scale.
1. Innovation Is No Longer the Bottleneck
One message came through clearly: innovation is no longer the limiting factor.
The conference highlighted a diversity of technologies: microbials, peptides, phages, RNA-based products, and synthetic biology platforms. The industry is full of ideas, data, and promising results.
Yet one comment captured the sentiment clearly. As Eva Hoo, General Manager at AgroPages, noted:
“Innovation is abundant, but scale remains elusive.”
This shows the industry is maturing. The challenge is no longer discovery; it is turning discoveries into real solutions. From lab to greenhouse. From greenhouse to field, then to farmer adoption.
This gap is the main point: most biological solutions struggle to move from research to real-world application.
2. Different Paths, Same Direction
Another interesting signal is how large companies are positioning themselves.
Instead of just buying new technologies, major global companies are taking on different roles in the ecosystem:
Some focus on technology development and platforms
Some act as integrators, combining biologicals into existing systems
Others explore new frameworks, such as biological-chemical synergy
Even with these different approaches, everyone is moving in the same direction:
Biologicals are becoming a core part of crop protection systems, not just a supplement.
This marks an important shift. The industry is moving beyond just trying biologicals and is beginning to integrate them into core crop protection strategies.
3. Technical Breakthroughs Are Real, But Cost Still Matters
The conference showcased impressive scientific progress:
Peptide-based solutions demonstrating strong field efficacy
RNA-based products expanding beyond insect control to fungi and mites
Bacteriophages advancing into practical field applications for bacterial disease control
Synthetic biology is improving production efficiency and scalability
Multi-omics approaches accelerating strain discovery and development
Some examples showed significant improvements in both cost and performance, with much lower production costs and strong field results, including microbial products from multiple players, RNA products developed by GreenLight Biosciences, and phage products from PhageLux AgriHealth.
If costs are high, adoption will be limited. Farmers decide based on reliability, simplicity, and cost, not just on how new or innovative something is.
It is a useful reminder for scientists: a good product should be measured not only by how well it works, but also by how easy it is to use and how affordable it is.
4. The Hidden Layer: Formulation, Delivery, and Field Stability
One important insight was realizing how many challenges exist between creating the active ingredient and making the final product.
We often focus on discovery: finding a new strain, identifying a new molecule, or designing a new RNA. But the real work often happens later: formulation, shelf life, delivery systems, and compatibility with existing practices.
These factors determine whether a product performs consistently in real-world conditions.
This work decides whether a product succeeds or fails.
5. Adoption Is a Behavioral Problem, Not Just a Technical One
Another point that stood out was how farmers adopt new solutions.
Mark Engel, Chairman of Phagelux AgriHealth, shared a very practical insight:
No farmer is willing to take the risk of replacing an old product they are already using.
This means biologicals usually need to be introduced slowly into the system as:
complements, not replacements
low-risk additions
bring higher ROI
part of an integrated pest management (IPM) program
Seen this way, gradual adoption is not a weakness. In fact, it is a strategy for long-term success. It also highlights something important: technology alone is not enough; trust matters just as much.
6. Regulation Is Evolving, But Not Yet Unified
Globally, regulatory systems for biologicals are still developing. Different regions progress at various speeds, with different definitions, requirements, and timelines.
For emerging technologies such as phages, RNA, and peptides, this creates both opportunities for innovation and uncertainty around market entry.
The regulatory system can handle new technologies. In practice, successful registration is not just about the product; it also requires clear positioning, strong science, reliable manufacturing, and early, transparent engagement with regulators.
7. The Real Bottleneck: Connecting the System
Putting these signals together, one takeaway becomes clear.
The main challenge is not a single piece of technology.
It is how everything connects.
From science to product.
From product to formulation.
From formulation to field performance.
From field performance to farmer trust.
From farmer trust to real adoption.
Each step matters. But more importantly, each step must connect and work well with the next.
The industry is shifting from competing on individual technologies to focusing on how everything works together as an integrated system.
Final Reflection
BioEx 2026 felt like a turning point.
Biologicals are no longer on the sidelines of agriculture; they are now part of the main conversation. But with that comes new responsibilities.
We need to think beyond discovery:
How do we design for real-world conditions?
How do we simplify adoption?
How do we align science, regulation, and application?
The future of biologicals will not be defined by a single breakthrough.
It will depend on how well we connect all the parts and how effectively we turn innovation into solutions that work in practice.
The next chapter will not be about new ideas alone, but about making those ideas work consistently, reliably, and at scale.
Comments